Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 296 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Roberto Vieira sold 296 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $100.82, for a total transaction of $29,842.72. Following the completion of the sale, the insider owned 3,946 shares in the company, valued at approximately $397,835.72. This trade represents a 6.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Roberto Wandenkolk Vieira also recently made the following trade(s):

• On Wednesday, September 2nd, Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock. The stock was sold at an average price of $110.76, for a total value of $6,460,963.08.

Corcept Therapeutics Trading Down 4.0%

Corcept Therapeutics stock traded down $4.57 during midday trading on Friday, hitting $110.29. The stock had a trading volume of 17,233,207 shares, compared to its average volume of 847,143. The business has a fifty day moving average price of $108.56 and a 200 day moving average price of $75.21. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38. The stock has a market cap of $11.92 billion, a P/E ratio of 262.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The company had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.Corcept Therapeutics’s quarterly revenue was up 31.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 EPS. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on CORT. Truist Financial assumed coverage on shares of Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price objective for the company. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research report on Monday, July 27th. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. HC Wainwright reaffirmed a “buy” rating and set a $165.00 price objective on shares of Corcept Therapeutics in a research report on Friday. Finally, Weiss Ratings lowered shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 8th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and an average target price of $138.17.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
• Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
• Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
• Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
• Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC acquired a new stake in Corcept Therapeutics in the second quarter worth $645,000. Tidal Investments LLC lifted its stake in Corcept Therapeutics by 9.2% in the second quarter. Tidal Investments LLC now owns 24,218 shares of the biotechnology company’s stock valued at $2,106,000 after buying an additional 2,039 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Corcept Therapeutics during the second quarter valued at $558,000. NewEdge Advisors LLC boosted its holdings in shares of Corcept Therapeutics by 17.9% during the second quarter. NewEdge Advisors LLC now owns 11,041 shares of the biotechnology company’s stock valued at $960,000 after acquiring an additional 1,677 shares during the period. Finally, IFP Advisors Inc grew its position in shares of Corcept Therapeutics by 568.4% during the second quarter. IFP Advisors Inc now owns 909 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 773 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.